NCT05735197View on ClinicalTrials.gov

Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

August 10, 2023

Study Completion Date

November 1, 2023

Conditions
Chronic Kidney DiseasesBone Diseases, Metabolic
Interventions
DRUG

Dapagliflozin 10mg Tab

Dapagliflozin which is (SGLT2 inhibitor) will be used as add on medication.

DRUG

Placebo

Placebo which has the same shape as Dapagliflozin but without active ingredient will be used as add on medication for control group.

Trial Locations (1)

35511

Urology and Nephrology center, Mansoura University, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER